Switzerland-based Anjarium Biosciences AG has expanded its leadership team with the appointment of Samantha Vieira as chief operating officer and Nate Massari as chief business officer. Mr Massari was most recently head of rare disease operations at Aytu BioPharma Inc which is developing drugs for genetic disorders and severe respiratory infections. He has also held leadership positions at Johnson & Johnson Inc, AstraZeneca Plc and Endo Pharmaceuticals Plc. Ms Vieira was previously commercial lead for retinal gene therapy at Biogen Inc. Before that, she worked at the UK start-up Nightstar Therapeutics Ltd which was acquired by Biogen in 2019. Anjarium is developing non-viral gene therapies.
Anjarium announced the appointments on 12 July 2022.
Copyright 2022 Evernow Publishing Ltd
